Aura Biosciences, Inc.
$7.05
▼
-2.39%
2026-04-21 05:29:00
www.aurabiosciences.com
NGM: AURA
Explore Aura Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$467.66 M
Current Price
$7.05
52W High / Low
$7.48 / $4.34
Stock P/E
—
Book Value
$2.15
Dividend Yield
—
ROCE
-74.67%
ROE
-73.52%
Face Value
—
EPS
$-1.76
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
113
Beta
0.35
Debt / Equity
12.69
Current Ratio
8.15
Quick Ratio
8.15
Forward P/E
-3.35
Price / Sales
—
Enterprise Value
$309.36 M
EV / EBITDA
-2.77
EV / Revenue
—
Rating
Strong Buy
Target Price
$20
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 2. | Pyxis Oncology, Inc. | $1.7 | — | $104.3 M | — | -119.93% | -91.44% | $5.55 / $0.89 | $0.85 |
| 3. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 4. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 5. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 6. | LENZ Therapeutics, Inc. | $10.13 | — | $319.19 M | — | -32.01% | -33.63% | $50.4 / $8.25 | $9.07 |
| 7. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -27.24 M | -27.91 M | -28.61 M | -29.04 M | -27.81 M | — |
| Net Profit | -25.56 M | -26.13 M | -27.02 M | -27.48 M | -25.83 M | — |
| EPS in Rs | -0.4 | -0.41 | -0.42 | -0.43 | -0.4 | -0.42 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -112.79 M | -96.12 M | -84.99 M | -60.3 M |
| Net Profit | -106.19 M | -86.92 M | -76.41 M | -58.76 M |
| EPS in Rs | -1.66 | -1.35 | -1.19 | -0.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 169.43 M | 182.5 M | 255.07 M | 223.94 M |
| Total Liabilities | 32.52 M | 30.53 M | 29.23 M | 28.35 M |
| Equity | 136.91 M | 151.97 M | 225.85 M | 195.58 M |
| Current Assets | 149.74 M | 160.62 M | 231.79 M | 196.7 M |
| Current Liabilities | 18.38 M | 14.91 M | 12.36 M | 10.46 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -84.74 M | -79.81 M | -63.85 M | -54.6 M |
| Investing CF | 35.59 M | 68.82 M | -113.96 M | -67.87 M |
| Financing CF | 77.16 M | 1.59 M | 97.29 M | 95.63 M |
| Free CF | -85.19 M | -81.06 M | -64.56 M | -55.7 M |
| Capex | -0.45 M | -1.25 M | -0.71 M | -1.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -13.76% | -30.03% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.